Article: Essential Therapeutics Reports ETRX 101 Results.

Essential Therapeutics, Inc. today announced that it has completed its Phase I trial for ETRX 101, and that based upon its review of the Phase I data and the data from recently completed non-clinical studies, the Company has decided not to continue the development of ETRX 101. The Company indicated that neither the Phase I data nor the non-clinical data generated by the Company showed signs of sufficient efficacy to support the continuation of development of ETRX 101 as a single agent. "We are obviously disappointed with the results of the ETRX 101 Phase I study and the non-clinical results we have received," said Mark Skaletsky, President and Chief Executive Officer of ...

Related newspaper, magazine, and journal articles:

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!